Real-Time Oncology Review (RTOR)
Real-Time Oncology Review (RTOR) Draft Guidance for Industry
Source: fda.gov
Expedited Programs News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Expedited Programs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Expedited Programs Today - Breaking & Trending Today
New FDA Guidance Clinical Trial Considerations To Support Accelerated Approval Of Oncology Therapeutics
On April 6, 2023, AbbVie announced that it was voluntarily withdrawing ibrutinib, which was granted accelerated approval for two indications: mantle...
Source: lifescienceleader.com
New FDA Guidance Clinical Trial Considerations To Support Accelerated Approval Of Oncology Therapeutics
On April 6, 2023, AbbVie announced that it was voluntarily withdrawing ibrutinib, which was granted accelerated approval for two indications: mantle...
Source: clinicalleader.com
FDA Issues First Untitled Letter Of The Year To HCT/P Manufacturer - Food and Drugs Law
On March 1, 2023, the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA) published its first untitled letter of the year to Thomas Advanced Medical LLC (Thomas)...
Source: mondaq.com
FDA New Untitled Letter to HCT/P Manufacturer
Center for Biologics Evaluation and Research CBER at Food and Drug Administration FDA published first untitled letter of the year to Thomas Advanced Medical LLC for marketing human cells, tissues, or cellular or tissue-based products HCT/Ps without FDA premarket review.
Source: natlawreview.com